Medical treatment of benign prostatic hyperplasia and instrumental alternatives

被引:0
作者
d'Urologie, Service [1 ]
机构
[1] Hop St Louis, Serv Urol, 1 Ave Claude Vellefaux, F-75084 Paris, France
来源
E-MEMOIRES DE L ACADEMIE NATIONALE DE CHIRURGIE | 2005年 / 4卷 / 01期
关键词
Benign prostatic hyperplasia; medical therapy; TUNA (transurethral needle ablation);
D O I
10.14607/emem.2005.1.04
中图分类号
R61 [外科手术学];
学科分类号
摘要
Clinical symptoms related to benign prostatic hyperplasia (BPH) combine obstructive and irritative symptoms. Obstructive symptoms, associating at different levels hesitancy, straining, weak flow and interrupted voiding, are related to the outflow obstruction due to the prostate itself through its mass and its tonus, while irritative symptoms, mainly diurnal and nocturnal frequency and urgency, are mostly due to detrusor abnormality, and to some extent to central nervous system disturbance. Prostatic outflow obstruction may be treated by alphablockers which reduce prostatic and bladder neck muscle tone, or by 5 alphareductase inhibitors which reduce glandular volume. Irritative symptoms may be treated by anti-muscarinic agents and at a lower degree by alphablockers. Plant extracts, which mechanism of action remains unclear, namely serenoa repens and pygeum africanum, are widely used in France. The place of instrumental alternatives remains to be determined but these instrumental treatments can now be regarded as possible alternatives to long life medical treatment rather than alternatives to a standard surgical treatment.
引用
收藏
页码:4 / 7
页数:4
相关论文
共 50 条
  • [21] LASER TREATMENT OF BENIGN PROSTATIC HYPERPLASIA
    MUSCHTER, R
    HOFSTETTER, A
    UROLOGE-AUSGABE A, 1994, 33 (04): : 281 - 287
  • [22] Individualization of treatment in benign prostatic hyperplasia
    Altwein, JE
    EUROPEAN UROLOGY, 1996, 29 : 2 - 6
  • [23] Dutasteride for the treatment of benign prostatic hyperplasia
    Wu, Christopher
    Kapoor, Anil
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (10) : 1399 - 1408
  • [24] Pharmacological treatment of benign prostatic hyperplasia
    Oelke, M.
    Kuczyk, M. A.
    Herrmann, T. R. W.
    UROLOGE, 2009, 48 (11): : 1365 - 1375
  • [25] Phytotherapy in the treatment of benign prostatic hyperplasia
    Bracher, F
    UROLOGE-AUSGABE A, 1997, 36 (01): : 10 - 17
  • [26] Tadalafil for the treatment of benign prostatic hyperplasia
    Monica, Fabiola Zakia
    De Nucci, Gilberto
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (08) : 929 - 937
  • [27] Options for the Treatment of Benign Prostatic Hyperplasia
    Plante, Mark
    Wachterman, Jared
    Perrapato, Scott
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2012, 22 (04): : 281 - 287
  • [28] Pharmacological treatment of benign prostatic hyperplasia
    Oelke, M.
    Martinelli, E.
    UROLOGE, 2016, 55 (01): : 81 - 94
  • [29] Medical therapy for benign prostatic hyperplasia progression
    McVary K.T.
    Current Urology Reports, 2002, 3 (4) : 269 - 275
  • [30] Association of the Benign Prostatic Hyperplasia and erectile dysfunction, the current treatment modalities in Benign Prostatic Hyperplasia
    Sen, Volkan
    Demir, Omer
    Esen, Ahmet Adil
    UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2011, 10 (04): : 62 - 64